Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04370704
Title Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Incyte Corporation


Advanced Solid Tumor


INCAGN02385 + INCAGN02390 + Retifanlimab

INCAGN02385 + INCAGN02390

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST